| pubmed-article:9001413 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9001413 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9001413 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:9001413 | lifeskim:mentions | umls-concept:C0079459 | lld:lifeskim |
| pubmed-article:9001413 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:9001413 | lifeskim:mentions | umls-concept:C0010711 | lld:lifeskim |
| pubmed-article:9001413 | lifeskim:mentions | umls-concept:C0020789 | lld:lifeskim |
| pubmed-article:9001413 | lifeskim:mentions | umls-concept:C0175668 | lld:lifeskim |
| pubmed-article:9001413 | lifeskim:mentions | umls-concept:C0221096 | lld:lifeskim |
| pubmed-article:9001413 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:9001413 | pubmed:dateCreated | 1997-2-11 | lld:pubmed |
| pubmed-article:9001413 | pubmed:abstractText | Using a combination of intensive chemotherapy and G-CSF, we conducted a prospective trial designed to improve the complete remission (CR) rate in patients with AML evolving from a primary documented myelodysplastic syndrome (sAML) and therapy-related AML (tAML). Thirty-four patients (median age 61 years) with sAML (25 patients) or tAML (nine patients) entered the study. Induction course consisted of idarubicin (12 mg/m2 of body-surface area per day for 3 days) and intermediate-dose (ID) cytarabine in the 24 younger patients (1 g/m2 of body-surface area as a 2 h infusion every 12 h for 5 days) or standard-dose (SD) cytarabine in the 10 older patients (100 mg/m2 of body-surface area per day as a continuous infusion for 7 days), followed by G-CSF until neutrophil recovery or treatment failure. Nineteen patients (56%, 13/24 in the ID group and 6/10 in the SD group) achieved a CR (14/25 sAML and 5/9 tAML). Early death occurred in four patients, but four additional patients died in CR from treatment-related toxicity (overall toxic death rate 24%). Initial cytogenetics was available in 33 patients. The CR rate was significantly lower in patients with unfavorable cytogenetics compared to patients with intermediate cytogenetics (37% vs 79%). Median remission duration and overall survival were 3 and 9 months, respectively and not different between ID and SD patients. Although the treatment-related toxicity is high, a high CR rate can be obtained in these poor-risk AML patients with the use of intensive chemotherapy in combination with G-CSF, although the role of the latter is still to be proven. Results remain especially poor in patients with unfavorable cytogenetics. New approaches are needed to maintain remission in these high-risk AML patients. | lld:pubmed |
| pubmed-article:9001413 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9001413 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9001413 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9001413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9001413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9001413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9001413 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9001413 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:9001413 | pubmed:issn | 0887-6924 | lld:pubmed |
| pubmed-article:9001413 | pubmed:author | pubmed-author:RousselotPP | lld:pubmed |
| pubmed-article:9001413 | pubmed:author | pubmed-author:MichelR PRP | lld:pubmed |
| pubmed-article:9001413 | pubmed:author | pubmed-author:ChaibiPP | lld:pubmed |
| pubmed-article:9001413 | pubmed:author | pubmed-author:DombretHH | lld:pubmed |
| pubmed-article:9001413 | pubmed:author | pubmed-author:de RevelTT | lld:pubmed |
| pubmed-article:9001413 | pubmed:author | pubmed-author:GardinCC | lld:pubmed |
| pubmed-article:9001413 | pubmed:author | pubmed-author:TurlurePP | lld:pubmed |
| pubmed-article:9001413 | pubmed:author | pubmed-author:NédellecGG | lld:pubmed |
| pubmed-article:9001413 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9001413 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:9001413 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9001413 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9001413 | pubmed:pagination | 16-21 | lld:pubmed |
| pubmed-article:9001413 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:meshHeading | pubmed-meshheading:9001413-... | lld:pubmed |
| pubmed-article:9001413 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9001413 | pubmed:articleTitle | Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Réflexion en Hématologie. | lld:pubmed |
| pubmed-article:9001413 | pubmed:affiliation | Department of Hematology, Hôpital Beaujon, Clichy, France. | lld:pubmed |
| pubmed-article:9001413 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9001413 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9001413 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:9001413 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
